Beigene

Beigene EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Beigene (6160.HK) as of Nov 12, 2026 is 37.81. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -30.58 — a change of -223.65% (higher).

EV/EBIT

37.81

YoY

-223.65%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Beigene is 2025 37.81 . EV/EBIT (Enterprise Value to EBIT) of Beigene was 2024 -30.58 . It decreases by -223.65% higher compared to the previous year.

The Beigene EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-18.10 USD
Jan 1, 2020
-71.07 USD
Jan 1, 2021
-12.08 USD
Jan 1, 2022
-9.71 USD
Jan 1, 2023
-14.39 USD
Jan 1, 2024
-30.58 USD
Jan 1, 2025
37.81 USD
Jan 1, 2026 (e)
8.64 USD
The Beigene EV/EBIT history
YEAREV/EBITYoY
est8.64-77.15%
37.81-223.65%
-30.58+112.56%
-14.39+48.18%
-9.71-19.61%
-12.08-83.01%
-71.07+292.65%
-18.10-26.47%
-24.62-86.05%
-176.46+18.89%
-148.42-51.52%
-306.17-72.23%
-1,102.61—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beigene Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Beigene's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Beigene's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Beigene's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Beigene grows earnings faster than its peers.

Beigene Stock analysis

What does Beigene do? Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beigene stock

EV/EBIT (Enterprise Value to EBIT) of Beigene is 37.81 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Beigene changed from -30.58 to 37.81, representing a -223.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Beigene since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Beigene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Beigene

All Key Metrics — Beigene